title: A patient with psoriasis and vitiligo treated with etanercept.
abstract: Psoriasis is a chronic, immune-mediated, inflammatory dermatosis whose aetiopathogenesis remains unclear, although tumour necrosis factor alpha (TNFalpha) appears to play a crucial role. The biological potential of TNFalpha inhibitors, such as etanercept, which reduce the inflammatory cascade, has radically changed the therapeutic management of patients with psoriasis and other immunomediated inflammatory diseases, associated with TNFalpha. The pathogenesis of the selective destruction of melanocytes in vitiligo is not fully understood, although there is growing evidence that several T helper type 1 cytokines, particularly TNFalpha, may be involved in the depigmentation process. A patient is described who presented with both psoriasis and vitiligo, and was treated with etanercept. After 24 weeks of therapy, the patient's psoriasis had improved markedly and the patient noted a mild improvement of vitiligo, with a reduction in macules and repigmentation in the scapular region.
authors.affiliation: Dermatological Clinic, Department of Biostatistics and Medical Information Technology Polytechnic Marche University, Via Conca 71, Ancona, Italy. a.campati@univpm.it
authors.forename: Anna
authors.initials: A
authors.lastname: Campanati
authors.forename: Katia
authors.initials: K
authors.lastname: Giuliodori
authors.forename: Giulia
authors.initials: G
authors.lastname: Ganzetti
authors.forename: Giulia
authors.initials: G
authors.lastname: Liberati
authors.forename: Anna Maria
authors.initials: AM
authors.lastname: Offidani
mesh_terms: D000368:Aged; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D007155:Immunologic Factors / Q000494:pharmacology / Q000627:therapeutic use; D008297:Male; D008544:Melanocytes / Q000378:metabolism; D011565:Psoriasis / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors; D014820:Vitiligo / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology
chemical_list: D007074:Immunoglobulin G; D007155:Immunologic Factors; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept